Current Hypertension Reports

, Volume 5, Issue 5, pp 386–392 | Cite as

Impact of the obesity epidemic on hypertension and renal disease

  • John E. Hall
  • Daniel W. Jones
  • Jay J. Kuo
  • Alexandre da Silva
  • Lakshmi S. Tallam
  • Jiankang Liu
Article

Abstract

Excess weight gain is a major cause of increased blood pressure in most patients with essential hypertension, and also greatly increases the risk for renal disease. Obesity raises blood pressure by increasing renal tubular reabsorption, impairing pressure natriuresis, causing volume expansion due to activation of the sympathetic nervous system and renin-angiotensin system, and by physical compression of the kidneys, especially when visceral obesity is present. The mechanisms of sympathetic nervous system activation in obesity may be due, in part, to hyperleptinemia that stimulates the hypothalamic pro-opiomelanocortin pathway. With prolonged obesity, there may be a gradual loss of nephron function that worsens with time and exacerbates hypertension. Weight reduction is an essential first step in the management of obesity hypertension and renal disease. Special considerations for the obese patient, in addition to adequately controlling the blood pressure, include correction of the metabolic abnormalities and protection of the kidneys from further injury.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hall JE, Jones DW: What can we do about the obesity epidemic? Am J Hypertens 2002, 15:657–665.PubMedCrossRefGoogle Scholar
  2. 2.
    Sorof J, Daniels S: Obesity hypertension in children—a problem of epidemic proportions. Hypertension 2002, 40:441–447. A thoughtful review of the cardiovascular consequences of obesity in children.PubMedCrossRefGoogle Scholar
  3. 3.
    Flegal KM, Carroll MD, Ogden CL, Johnson CCL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727. An important survey of 4115 adult men and women conducted in 1999 and 2000 as part of the NHANES documenting the rapid increase in the prevalence of obesity in adults in the United States.PubMedCrossRefGoogle Scholar
  4. 4.
    Ogden CL, Flegal KM, Carroll MD, Johnson CL: Prevalence and trends in overweight among US children and adolescents. JAMA 2002, 288:1728–1732.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson PWF, D’Agostino RB, Sullivan L, et al.: Overweight and obesity as determinants of cardiovascular risk—the Framingham experience. Arch Intern Med 2002, 162:1867–1872.PubMedCrossRefGoogle Scholar
  6. 6.
    Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127–137. This paper provides a comprehensive review of the pathophysiologic mechanisms by which obesity causes cardiovascular and renal disease.PubMedCrossRefGoogle Scholar
  7. 7.
    Hall JE, Kuo JJ, Silva A, et al.: Obesity, hypertension and renal disease. Curr Opin Nephrol Hypertens 2003, 12:195–200.PubMedCrossRefGoogle Scholar
  8. 8.
    Wannamethee SG, Shaper AG: Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999, 22:1266–1272.PubMedCrossRefGoogle Scholar
  9. 9.
    Sundquist J, Winkeby MA, Pudaric S: Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III; 1988–1994. J Am Geriatr Soc 2001, 49:109–116.PubMedCrossRefGoogle Scholar
  10. 10.
    He Q, Ding YZ, Fong DY, Karlberg J: Blood pressure is associated with body mass index in both normal and obese children. Hypertension 2000, 36:165–170.PubMedGoogle Scholar
  11. 11.
    Garrison RJ, Kannel WB, Stokes J, et al.: Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987, 16:235–251.PubMedCrossRefGoogle Scholar
  12. 12.
    Hall JE, Jones DW, Henegar J, et al.: Obesity hypertension, and renal disease. In Obesity: Mechanisms and Clinical Management. Edited by Eckel RH. Philadelphia: Lippincott, Williams & Wilkins; 2003:273–300.Google Scholar
  13. 13.
    Cooper RS, Potimi CN, Ward R: The puzzle of hypertension in African-Americans. Sci Am 1999, 280:56–63.PubMedGoogle Scholar
  14. 14.
    He J, Whelton PK, Appel LJ, et al.: Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2001, 35:544–549.Google Scholar
  15. 15.
    Miller ER, Erlinger TP, Young DR, et al.: Results of the diet, exercise, and weight loss intervention trial (DEW-IT). Hypertension 2002, 40:612–618.PubMedCrossRefGoogle Scholar
  16. 16.
    Dobrian AD, Davies MJ, Schriver SD, et al.: Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001, 37:554–560.PubMedGoogle Scholar
  17. 17.
    Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41:625–633.PubMedCrossRefGoogle Scholar
  18. 18.
    Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and the sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S.PubMedCrossRefGoogle Scholar
  19. 19.
    Esler M, Rumantir M, Wiesner G, et al.: Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001, 14:304S-309S.PubMedCrossRefGoogle Scholar
  20. 20.
    Abate NI, Mansour YH, Arbique D, et al.: Overweight and sympathetic activity in black Americans. Hypertension 2001, 38:379–383.PubMedGoogle Scholar
  21. 21.
    Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694–698.PubMedCrossRefGoogle Scholar
  22. 22.
    Kassab S, Kato T, Wilkins C, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893–897.PubMedGoogle Scholar
  23. 23.
    Grassi G, Seravalle G, Dell’Oro R, et al.: Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000, 36:538–542.PubMedGoogle Scholar
  24. 24.
    Weyer C, Pratley RE, Snitker S, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531–537.PubMedGoogle Scholar
  25. 25.
    Alvarez GE, Beske SD, Ballard TP, Davy KP: Sympathetic neural activation in visceral obesity. Circulation 2002, 106:2533–2536.PubMedCrossRefGoogle Scholar
  26. 26.
    Grassi G, Seravalle G, Dell’Oro R, et al.: Participation of the hypothalamus-hypophysis axis in the sympathetic activation of human obesity. Hypertension 2001, 38:1316–1320.PubMedGoogle Scholar
  27. 27.
    Eikelis N, Schlaich M, Aggarwal A, et al.: Interactions between leptin and the human sympathetic nervous system hypertension. Hypertension 2003, 41:1072–1079.PubMedCrossRefGoogle Scholar
  28. 28.
    Jequier E: Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002, 967:379–388. An excellent and comprehensive review of the pathways of leptin signaling and their role in regulating energy balance.PubMedCrossRefGoogle Scholar
  29. 29.
    Correia MLG, Morgan DA, Sivitz WI, et al.: Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 2001, 37:936–942.PubMedGoogle Scholar
  30. 30.
    Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409–414.PubMedGoogle Scholar
  31. 31.
    Kuo JJ, Jones OB, Hall JE: Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001, 37:670–676.PubMedGoogle Scholar
  32. 32.
    Carlyle M, Jones OB, Kuo JJ, Hall JE: Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002, 39:496–501.PubMedCrossRefGoogle Scholar
  33. 33.
    Aizawa-Abe M, Ogawa Y, Mazuzaki H, et al.: Pathophysiological role of leptin in obesity related hypertension. J Clin Invest 2000, 105(9):1243–1252.PubMedCrossRefGoogle Scholar
  34. 34.
    Mark AL, Shaffer RA, Correia ML, et al.: Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow mice. J Hypertens 1999, 17:1949–1953.PubMedCrossRefGoogle Scholar
  35. 35.
    Ozata M, Ozdemir IC, Licinio J: Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999, 10:3686–3695.CrossRefGoogle Scholar
  36. 36.
    Haynes WG, Morgan DA, Djalali A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33:542–547.PubMedGoogle Scholar
  37. 37.
    Kuo JJ, Silva AA, Hall JE: Hypothalamic melanocortin receptors and chronic regulation of arterial pressure and renal function. Hypertension 2003, 41:768–774.PubMedCrossRefGoogle Scholar
  38. 38.
    Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609–611.PubMedCrossRefGoogle Scholar
  39. 39.
    Reisen E, Weir M, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A Multicenter Placebo-Controlled Trial. Hypertension 1997, 30:140–145.Google Scholar
  40. 40.
    Zanella MT, Kohlmann Jr O, Ribeiro AB: Treatment of Obesity Hypertension and Diabetes Syndrome. Hypertension 2001, 38:705–708.PubMedGoogle Scholar
  41. 41.
    Morales E, Valero MA, Leon M, et al.: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41:319–327.PubMedCrossRefGoogle Scholar
  42. 42.
    Kambham N, Markowitz GS, Valeri AM, et al.: Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498–1509.PubMedCrossRefGoogle Scholar
  43. 43.
    Henegar JR, Bigler SA, Henegar LK, et al.: Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001, 12:1211–1217.PubMedGoogle Scholar
  44. 44.
    Assmann G, Schulte H: The Prospective Cardiovascular Munster Study (PROCAM): prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary artery disease. Am Heart J 1988, 1116:1713–1724.CrossRefGoogle Scholar
  45. 45.
    Praga M, Hernandez E, Herrero JC, et al.: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000, 58:2111–2118.PubMedCrossRefGoogle Scholar
  46. 46.
    Stern JS, Gades MD, Wheeldon CM, Borchers AT: Calorie restriction in obesity: prevention of kidney disease in rodents. J Nutr 2001, 131:913S-917S.PubMedGoogle Scholar
  47. 47.
    National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. 1998. National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases. http:// www.nhlbi.nih.gov/guidelines/index.htm. Accessed July, 2003.Google Scholar
  48. 48.
    Sharma AM, Pischon T, Engeli S, et al.: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667–674.PubMedCrossRefGoogle Scholar
  49. 49.
    Oparil S: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. Hypertension 2003, 41:1006–1009.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • John E. Hall
    • 1
  • Daniel W. Jones
  • Jay J. Kuo
  • Alexandre da Silva
  • Lakshmi S. Tallam
  • Jiankang Liu
  1. 1.Department of Physiology and BiophysicsUniversity of Mississippi Medical CenterJacksonUSA

Personalised recommendations